Retatrutide, a experimental dual agonist of the GLP-1 binding site and glucose-dependent insulinotropic polypeptide (GIP) target, is showing promising outcomes in preliminary clinical trials . Recent https://baidubookmark.com/story21204614/retatrutide-emerging-studies-and-potential-medical-applications